Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-herpes treatment found to reduce genital and plasma HIV levels in women infected with both HIV and herpes viruses

22.02.2007
Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published Treating women who are infected with both the HSV-2 and HIV viruses with anti-herpes treatment can reduce the amount of HIV in the blood and genital secretions, according to the results of a trial published today in the New England Journal of Medicine.

A collaborative group of scientists from the Centre Muraz (Burkina Faso), the University of Montpellier (France) and the London School of Hygiene & Tropical Medicine (UK) carried out the trial among women co-infected with the human immuno-deficiency virus (HIV) and the virus that causes genital herpes (HSV-2) in Burkina Faso. The results showed that having the herpes virus increased the replication of HIV, and also revealed that the quantity of HIV in the blood and in the vagina was reduced by continuous anti-herpes treatment over 3 months.

These findings open new avenues for the prevention of HIV transmission and for the management of patients co-infected by the two viruses.

In 2005, an estimated 4.1 million people were newly infected with HIV, mostly through heterosexual intercourse1. This alarming number of infections highlights the urgent need to intensify and expand proven prevention methods, and further, to identify and implement new methods of HIV prevention.

... more about:
»Genital »HIV »HSV »HSV-2 »Herpes »Vaccine

A number of observational studies have indicated that HSV-2 enhances the risk of HIV-1 acquisition by around three-fold2. HSV-2 infection may also increase HIV-1 infectiousness by disrupting the genital mucosa and increasing the levels of HIV in the genital tract3, allowing easier transmissibility of the virus. In addition, the HIV viral load in the blood of HIV-1 infected patients increases, at least temporarily, during episodes of HSV reactivation.

Lead author Dr. Nicolas Nagot, of the London School of Hygiene & Tropical Medicine (LSHTM), explains: ‘Behavioural interventions are not always successful, as knowledge does not necessarily translate into sexual behaviour change. Therefore, innovative methods that target the biological susceptibility of individuals to acquire or transmit HIV are also required. A number of options to prevent HIV transmission are currently being investigated, including the role of vaginal microbicides, pre-exposure HIV prophylaxis, male circumcision, and - in the future - an HIV vaccine.’

‘The results of the trial are striking’, he adds. ‘They show that valacyclovir significantly reduces the frequency and quantity of HIV detectable in genital secretions and, in addition, reduces the quantity of HIV in the plasma. As expected, there was also dramatic reduction in the detection of symptomatic and asymptomatic presence of HSV-2. The effects appeared to gradually increase over the 3 month follow-up period, with no sign of abating.’

These results indicate a new way to possibly reduce the sexual transmission of HIV from already infected individuals to their partners, since the frequency and quantity of HIV in the female genital tract are closely related to the transmission of the virus.

The findings will need to be confirmed by further research, and there is already a large ongoing trial that is measuring direct transmission of HIV between discordant couples in several sites worldwide.

Dr Philippe Mayaud, one of Dr Nagot’s colleagues at the LSHTM concludes: ‘Our results have important potential implications for public health and clinical practice, as HSV-2 control could become a new form of HIV prevention targeting HIV-infected individuals, as well as providing clinical benefits. Importantly, an HSV vaccine that would either prevent HSV infection or diminish the clinical and sub-clinical manifestations of HSV with a similar efficacy on HIV as HSV suppressive therapy, would represent a long-lasting form of HIV prevention. The development and evaluation of an HSV vaccine should rank high on the international research agenda.’

Gareth Thomas, UK Minister for International Development, whose department DFID has provided supplementary funding for the research, said: "These exciting initial findings demonstrate why research into reducing HIV/ AIDS transmission is such a vital element of the fight against the disease. The UK Government has pledged to spend £1.5 billion tackling HIV/AIDS in developing countries between 2005 and 2008. We will follow the next stages of this research with interest."

Philippe Mayaud | alfa
Further information:
http://www.lshtm.ac.uk

Further reports about: Genital HIV HSV HSV-2 Herpes Vaccine

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

 
Latest News

Supercomputing helps researchers understand Earth's interior

23.05.2017 | Earth Sciences

Study identifies RNA molecule that shields breast cancer stem cells from immune system

23.05.2017 | Life Sciences

Turmoil in sluggish electrons’ existence

23.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>